	US 12,298,311 B2
	Immunological biomarker for predicting clinical effect of cancer
Hiroshi Kagamu, Saitama (JP)
Assigned to Saitama Medical University, Saitama (JP)
Filed by Saitama Medical University, Saitama (JP)
Filed on Feb. 25, 2022, as Appl. No. 17/681,616.
Application 17/681,616 is a continuation of application No. 16/484,071, granted, now 11,293,924, previously published as PCT/JP2018/004090, filed on Feb. 6, 2018.
Claims priority of application No. 2017-020685 (JP), filed on Feb. 7, 2017; and application No. 2017-110069 (JP), filed on Jun. 2, 2017.
Prior Publication US 2022/0178933 A1, Jun. 9, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/574 (2006.01); A61K 39/00 (2006.01); A61K 40/11 (2025.01); A61K 40/42 (2025.01); C07K 16/18 (2006.01); C07K 16/28 (2006.01)

CPC G01N 33/57492 (2013.01) [A61K 40/11 (2025.01); A61K 40/42 (2025.01); C07K 16/18 (2013.01); C07K 16/2812 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/57 (2023.05); G01N 2333/70514 (2013.01); G01N 2333/70564 (2013.01); G01N 2333/7155 (2013.01)]

6 Claims

1. A method of predicting a response to cancer immunotherapy of a subject, the method comprising:

measuring an amount of CD4⁺CD62L^lowT-cells of the subject (X);

comparing X with an ineffective group threshold value, wherein an amount of X that is higher than the ineffective group threshold value indicates that the subject is not a part of an ineffective group to the cancer immunotherapy; and

applying a cancer immunotherapy to the subject predicted to be not a part of an ineffective group;

wherein the cancer immunotherapy comprises administration of an immune checkpoint inhibitor; and

wherein X is a ratio of a CD62L^lowCD4⁺ T-cell subpopulation in CD4⁺ T-cells.